Ed Fanning is quoted in Law360’s reporting on the New Jersey Supreme Court’s ruling that found labels on Hoffmann-LaRoche’s acne drug Accutane were adequate under New Jersey law. Ed, who represented amicus curiae Healthcare Institute of New Jersey in the case, notes that “the decision is consistent with what we advocated and it’s consistent with prior New Jersey law,” and adds that the ruling “confirms that plaintiffs who have flocked to New Jersey from other states to sue our pharmaceutical companies are going to be subject to that heightened protection that is afforded to companies in New Jersey.”
Click to read the full article: “NJ Justices Say Garden State Law Topples Accutane Cases“